Y-S. Lu - Department of Internal Medicine, National Taiwan University Hospital

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 24 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

LBA2 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in pretreated, inoperable/metastatic HR+/HER2– breast cancer (BC): Additional safety analysis from TROPION-Breast01

K. Jhaveri, A. Bardia,S-A. Im, S. Pernas Simon,M. De Laurentiis, S. Wang, N. Martinez, G. Santos Borges, D.W. Cescon, M. Hattori,Y-S. Lu, E.P. Hamilton,

ESMO Open (2024)

引用0浏览0引用

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer

K.H. Park, S. Loibl, J. Sohn,Y.H. Park, Z. Jiang, H. Tadjoedin, S. Nag, S. Saji, M. Md. Yusof, E.M.B. Villegas, E.H. Lim,Y.-S. Lu,

ESMO Openpp.102974, (2024)

引用0浏览0引用

57MO First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in HR+/HER2− advanced breast cancer (ABC): A post hoc analysis of Asian and non-Asian patients (pts) from the phase II RIGHT choice trial

Y-S. Yap,S-A. Im,Y-S. Lu, H.A. Azim, Y. Eralp, G.B. Kanakasetty, H. Abdel-Razeq, L. Zhukova, A. Thuerigen, T. Delgar Alfaro, J. Wu,M. Gao,

Annals of Oncology（2023）

引用0浏览0引用

LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial

A. Bardia, K. Jhaveri,S-A. Im, S. Pernas Simon,M. De Laurentiis, S. Wang, N. Martinez, G. Santos Borges, D.W. Cescon, M. Hattori,Y-S. Lu, E.P. Hamilton,

Annals of Oncology (2023): S1264-S1265

引用0浏览0引用

Capivasertib (C) plus fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2e advanced breast cancer (ABC): Phase III CAPItello-291 trial Chinese cohort

X. Hu,Q. Zhang, T. Sun, H. Xiong,W. Li, Y. Teng,Y-S. Lu,L-M. Tseng, M. Yan,H. Li, D. Pang,S. C. Chen,

ANNALS OF ONCOLOGY (2023): S1485-S1486

引用0浏览0引用

Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)

S. C. Lee,Y. H. Park, C. Singer, J. Balmana, R. A. Dent, V. K. Tan, N. A. M. Sari, M. Md Yusof, F. V. F. Que,Y-S. Lu, N. Parinyanitikul, C. P. Pham,

ANNALS OF ONCOLOGY (2023): S1475-S1476

引用0浏览0引用

LBA5 Capivasertib (C) + fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Phase III CAPItello-291 trial Chinese cohort

X. Hu,Q. Zhang, T. Sun, H. Xiong,W. Li, Y. Teng,Y-S. Lu,L-M. Tseng, M. Yan,H. Li, D. Pang,S.C. Chen,

Annals of Oncology（2023）

引用0浏览0引用

First-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in HR+/HER2L advanced breast cancer (ABC): A post hoc analysis of Asian and non-Asian patients (pts) from the phase II RIGHT choice trial

Y-S. Yap,S-A. Im,Y-S. Lu, H. A. Azim, Y. Eralp, G. B. Kanakasetty, H. Abdel-Razeq, L. Zhukova, A. Thuerigen, T. Delgar Alfaro, J. Wu,M. Gao,

ANNALS OF ONCOLOGY (2023): S1488-S1488

引用0浏览0引用

192MO DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC)

D.A.A. Cameron, W. Jacot, T. Yamashita,M.J. Vidal Losada, P. Schmid,K.S. Lee,M. De Laurentiis, F. Zagouri, N.T. Ueno, A. Prat, N. Harbeck, R. Yerushalmi,

ESMO Openno. 1 (2023): 101381-101381

引用1浏览0引用

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

F André,E M Ciruelos,D Juric,S Loibl,M Campone,I A Mayer,G Rubovszky,T Yamashita,B Kaufman,Y-S Lu,K Inoue, Z Pápai,

Annals of Oncology（2021）

引用251浏览0WOS引用

251

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn